[Continuation of ACEI/ARB treatment in patients diagnosed with COVID-19].
作者信息
Ávila Cabreja José Alejandro, García Méndez Felicia María, Sosa González Ismael, Zayas Fundora Emmanuel
机构信息
Facultad de Ciencias Médicas Manuel Fajardo, Universidad de Ciencias Médicas de La Habana, La Habana, Cuba.
Facultad de Ciencias Médicas Manuel Fajardo, Universidad de Ciencias Médicas de La Habana, La Habana, Cuba.
出版信息
Aten Primaria. 2021 Jun-Jul;53(6):102068. doi: 10.1016/j.aprim.2021.102068. Epub 2021 Mar 30.
Abstract
摘要
相似文献
1
[Continuation of ACEI/ARB treatment in patients diagnosed with COVID-19].确诊新冠肺炎患者继续使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂治疗
Aten Primaria. 2021 Jun-Jul;53(6):102068. doi: 10.1016/j.aprim.2021.102068. Epub 2021 Mar 30.
2
Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.COVID-19 综合征住院后血管紧张素转换酶抑制剂或血管紧张素 II 受体拮抗剂的预先给药与生存。
J Am Heart Assoc. 2020 Nov 17;9(22):e017364. doi: 10.1161/JAHA.120.017364. Epub 2020 Oct 7.
3
Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.低体重指数是与血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂治疗相关的高钾血症的一个危险因素。
J Clin Pharm Ther. 2018 Dec;43(6):829-835. doi: 10.1111/jcpt.12720. Epub 2018 Jun 16.
4
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality.2019冠状病毒病中继续使用与停用血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂：对血压控制和死亡率的影响
Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412-414. doi: 10.1093/ehjcvp/pvaa056.
5
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.住院 COVID-19 合并高血压患者中血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂的住院使用率与死亡率的关系。
Circ Res. 2020 Jun 5;126(12):1671-1681. doi: 10.1161/CIRCRESAHA.120.317134. Epub 2020 Apr 17.
6
Shining More Light on RAS Inhibition during the COVID-19 Pandemic.在新冠疫情期间，进一步揭示RAS抑制作用
Clin J Am Soc Nephrol. 2021 Jul;16(7):1002-1004. doi: 10.2215/CJN.06000521. Epub 2021 Jul 12.
7
Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.长期使用 ACEI/ARB 与法国东北部转诊中心队列中重症 COVID-19 患者的严重肾功能障碍和急性肾损伤相关。
Clin Infect Dis. 2020 Dec 3;71(9):2447-2456. doi: 10.1093/cid/ciaa677.
8
Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.单纯糖尿病患者中联合使用肾素-血管紧张素系统抑制剂和PPARγ激动剂导致的贫血
Exp Clin Endocrinol Diabetes. 2012 Jul;120(7):416-9. doi: 10.1055/s-0032-1306286. Epub 2012 Mar 22.
9
Stopping RAS Inhibitors to Minimize AKI: More Harm than Good?停用肾素-血管紧张素系统（RAS）抑制剂以减少急性肾损伤：弊大于利？
Clin J Am Soc Nephrol. 2019 Apr 5;14(4):617-619. doi: 10.2215/CJN.14021118. Epub 2019 Feb 27.
10
COVID-19, hypertension, and renin-angiotensin-aldosterone system inhibitors: Much ado about nothing or real problem to be solved?新型冠状病毒肺炎、高血压与肾素-血管紧张素-醛固酮系统抑制剂：小题大做还是亟待解决的实际问题？
J Clin Hypertens (Greenwich). 2020 Nov;22(11):1984-1986. doi: 10.1111/jch.14045. Epub 2020 Sep 20.
Zotero 插件